Drugs / APH-1105
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT03806478 | Jun 2023 → Sep 2024 | Alzheimer disease 2, Alzheimer disease 3, Alzheimer disease type 1 | Aphios | Unknown | No outcome recorded |
Evidence & citations 2 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | APH-1105 | ClinicalTrials.gov intervention name — accepted as the source's own label NCT03806478 ↗ |
| Route | Intranasal | “intended for intranasal administration.” NCT03806478 ↗ |